Gables Capital Management’s Lexaria Bioscience LEXX Stock Holding History

Gables Capital Management’s Portfolio LEXX Stock Details LEXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7	Hold	1	–	–	﹤0.01%	507
2026 Q1	$10	Hold	1	–	–	﹤0.01%	471
2025 Q4	$8	Hold	1	–	–	﹤0.01%	463
2025 Q3	$12	Hold	1	–	–	﹤0.01%	457
2025 Q2	$11	Hold	1	–	–	﹤0.01%	442
2025 Q1	$22	Hold	1	–	–	﹤0.01%	442
2024 Q4	$27	Hold	1	–	–	﹤0.01%	443
2024 Q3	$40	Hold	1	–	–	﹤0.01%	443
2024 Q2	$36	Hold	1	–	–	﹤0.01%	394
2024 Q1	$47	Hold	1	–	–	﹤0.01%	388
2023 Q4	$16	Hold	1	–	–	﹤0.01%	377
2023 Q3	$13	Buy	+1	New	+$14	﹤0.01%	363
2023 Q2	–	Sell	-1	Closed	-$35	–	379
2023 Q1	$35	Hold	1	–	–	﹤0.01%	374
2022 Q4	$32	Hold	1	–	–	﹤0.01%	358
2022 Q3	$0	Hold	1	–	–	﹤0.01%	346
2022 Q2	$0	Hold	1	–	–	﹤0.01%	354
2022 Q1	$0	Hold	1	–	–	﹤0.01%	349
2021 Q4	$0	Hold	1	–	–	﹤0.01%	354
2021 Q3	$0	Buy	+1	New	+$96	﹤0.01%	358

Other funds holding LEXX

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Gables Capital Management's LEXX Position: Q2 2026 in Review

Gables Capital Management held its Lexaria Bioscience (LEXX) position steady in Q2 2026 at 1 share worth $7. The position accounts for ﹤0.01% of the portfolio, ranked #507.

Gables Capital Management first reported a position in LEXX in Q3 2021 and has held it in 19 quarters since. The position peaked at $47 in Q1 2024. 29 funds tracked by Wall St. Rank hold LEXX as of Q2 2026.

Gables Capital Management held 1 share of Lexaria Bioscience worth $7 as of Q2 2026.
Gables Capital Management left its Lexaria Bioscience share count unchanged in Q2 2026.
Lexaria Bioscience made up ﹤0.01% of Gables Capital Management's portfolio in Q2 2026, its #507 holding.
Gables Capital Management first reported a position in Lexaria Bioscience in Q3 2021 and has held it in 19 quarters since.
Gables Capital Management's Lexaria Bioscience position peaked at $47 in Q1 2024.
29 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q2 2026.

Based on Gables Capital Management's 13F filing for Q2 2026, filed 10 Aug 2026.